Ellevest, Inc. Editas Medicine, Inc. Transaction History

Ellevest, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 18, 2022	SELL	$9.99 - $21.35 $129 - $277	-13 Closed	0 $0
Q1 2022 Apr 19, 2022	SELL	$14.08 - $27.63 $225 - $442	-16 Reduced 55.17%	13 $0
Q3 2021 Oct 19, 2021	SELL	$39.27 - $72.94 $117 - $218	-3 Reduced 9.38%	29 $1,000
Q2 2021 Jul 13, 2021	BUY	$31.29 - $56.64 $93 - $169	3 Added 10.34%	32 $2,000
Q4 2020 Feb 04, 2021	BUY	$27.07 - $84.35 $297 - $927	11 Added 61.11%	29 $2,000
Q3 2020 Oct 26, 2020	BUY	$28.06 - $37.16 $336 - $445	12 Added 200.0%	18 $1,000
Q2 2020 Jul 06, 2020	BUY	$18.5 - $34.34 $111 - $206	6 New	6 $0
Q1 2020 Apr 13, 2020	SELL	$14.88 - $32.78 $550 - $1,212	-37 Closed	0 $0
Q4 2019 Feb 05, 2020	BUY	$19.49 - $32.63 $721 - $1,207	37 New	37 $1,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Ellevest, Inc., based on Form 13F filings with the SEC.

Stay updated on Ellevest, Inc. with notifications on news.